Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, has won approval for the sale of its CellSpray treatment in Greece, with shares rising on the news.
Shares rose 4.7 per cent on the news to 8.9c each at 10:00 WST.
The full text of a company announcement is pasted below
CELLSPRAY® APPROVED IN GREECE
8 November 2006: Clinical Cell Culture Ltd (C3, ASX: CCE) today announced that the Greek Health Authorities have approved CellSpray® for commercial sales in Greece.
CellSpray® is a suspension containing cultured skin cells for use in the treatment of major burns and scars. Cells are harvested from a small biopsy and cultured in C3's laboratory for approximately 5 to 7 days and then reapplied to the wound. Traditional technologies take approximately 21 days to culture small sheets of skin.
C3 Chief Executive Officer Bob Atwill said he was delighted that regulatory approval for CellSpray® had been received in another European market.
"We are looking forward to building on the recent success of CellSpray® in Germany and the first patient treatment in the UK. Greece is an important European market and we expect commercial sales to commence during the current quarter," said Mr Atwill.
CellSpray® is now approved for sale in 6 European countries, Austria, Denmark, Germany, Greece, The Netherlands and the UK.
